User:Laceypage/Ketamine-assisted psychotherapy
Ketamine is a short-acting, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist.[1] It was discovered by Parke-Davis Labs and Dr. Calvin Lee Stevens in 1962 during research into derivatives of phencyclidine (PCP).[2] It was first used clinically as a veterinary anesthetic. Edward Domino administered the first dose of ketamine to a human in the year 1964. Soon after, Parke-Davis filed a patent for the utilization of the anesthetic.[3][4] Given its hallucinogenic properties, interest rapidly rose in the possibility of broader avenues of application, including within the field of psychiatry as a treatment for depression, substance use dependence, and more.[5] The US Food and Drug Administration (FDA) first approved the use of intranasal esketamine (Spravato)—an enantiomer of ketamine—for the use of ketamine-derived therapy for treatment-resistant depression, in 2019.[6] Ketamine is currently one of the two injected general anaesthetics that the World Health Organisation includes in its Model List of Essential Medicines.
 | This is the sandbox page where you will draft your initial Wikipedia contribution.
If you're starting a new article, you can develop it here until it's ready to go live. If you're working on improvements to an existing article, copy only one section at a time of the article to this sandbox to work on, and be sure to use an edit summary linking to the article you copied from. Do not copy over the entire article. You can find additional instructions here. Remember to save your work regularly using the "Publish page" button. (It just means 'save'; it will still be in the sandbox.) You can add bold formatting to your additions to differentiate them from existing content. |
Article Draft[edit]
Lead[edit]
Article body[edit]
References[edit]
- ^ Drozdz, Sandra J; Goel, Akash; McGarr, Matthew W; Katz, Joel; Ritvo, Paul; Mattina, Gabriella F; Bhat, Venkat; Diep, Calvin; Ladha, Karim S (2022-12-31). "Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature". Journal of Pain Research. 15: 1691–1706. doi:10.2147/JPR.S360733. PMC 9207256. PMID 35734507.
- ^ Mathai, David S.; Mora, Victoria; Garcia-Romeu, Albert (2022). "Toward Synergies of Ketamine and Psychotherapy". Frontiers in Psychology. 13: 868103. doi:10.3389/fpsyg.2022.868103. ISSN 1664-1078. PMC 8992793. PMID 35401323.
- ^ "History of Ketamine". TD Consultancy. Retrieved 2023-12-05.
- ^ Le Daré, B.; Pelletier, R.; Morel, I.; Gicquel, T. (2022-01). "[History of Ketamine: An ancient molecule that is still popular today]". Annales Pharmaceutiques Francaises. 80 (1): 1–8. doi:10.1016/j.pharma.2021.04.005. ISSN 0003-4509. PMID 33915159.
{{cite journal}}: Check date values in:|date=(help) - ^ Dore, Jennifer; Turnipseed, Brent; Dwyer, Shannon; Turnipseed, Andrea; Andries, Julane; Ascani, German; Monnette, Celeste; Huidekoper, Angela; Strauss, Nicole; Wolfson, Phil (2019-03-15). "Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy". Journal of Psychoactive Drugs. 51 (2): 189–198. doi:10.1080/02791072.2019.1587556. ISSN 0279-1072. PMID 30917760. S2CID 85543704.
- ^ Research, Center for Drug Evaluation and (2022-02-16). "FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray". FDA.